Work Package 3

Work Package 3 Clinical Imaging

Work Package 3 provides a prototype matrix and infrastructure for rapid validation of imaging biomarkers to evaluate response to therapy. Imaging biomarkers for proliferation and apoptosis are being validated for use with currently available drug classes. This research matrix sets the stage for swift evaluation of new anticancer drug classes and regimens as well as informing on other biological aspects of drug action, applicable in a multicenter setting and in phase I/II therapeutic trials.

Participating QuIC-ConCePT partners:

  1. European Organisation for Research and Treatment of Cancer, AISBL, Belgium
  2. Universitair Ziekenhuis Antwerpen, Belgium
  3. The Institute of Cancer Research – Royal Marsden, United Kingdom
  4. VUmc Amsterdam, The Netherlands
  5. Manchester Cancer Research Centre, United Kingdom
  6. European Institute for Molecular Imaging at the Westfaelische Wilhelms-Universitaet Muenster, Germany
  7. Radboud University Nijmegen Medical Center, The Netherlands
  8. Imperial College London, United Kingdom
  9. Université Paris Diderot (INSERM)
  10. AstraZeneca, UK
  11. Eli Lilly and Company Ltd, United Kingdom
  12. GlaxoSmithKline R&D Ltd, United Kingdom
  13. Merck KgAA, Germany
  14. F. Hoffmann-La Roche AG, Switzerland
  15. Amgen NV, Belgium

Imaging Guidelines

QuIC-ConCePT has 15 separate clinical trials in patients with lung and liver malignancies to achieve technical (assay) validation. This includes repeatability, reproducibility, advanced image analysis to overcome motion artefact, and accuracy (using specially devised phantoms). The acquisition protocols have been optimized, simplified and clinical feasible. The imaging guidelines can be found through the below links:

IMI oncology projects